# A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

> **NCT00393484** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 122 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Lamivudine Placebo
- **DRUG:** Lamivudine
- **DRUG:** Entecavir Placebo

## Key facts

- **NCT ID:** NCT00393484
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-01
- **Final completion:** 2013-09
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2014-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393484, "A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00393484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*